BEIJING, March 27, 2026 — Sinovac Holding Group (“SINOVAC”) and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 20

BEIJING, January 27, 2026 – Co-administration of SINOVAC's Sabin-strain inactivated poliovirus vaccine (sIPV) with either measles-mumps-rubella (MMR) or inactivated hepatitis A (HepA) vaccines is

BEIJING, January 22, 2026 – Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (

BEIJING, January 20, 2026 – A large-scale real-world study published in the peer-reviewed journal Vaccines showed that SINOVAC's live attenuated varicella vaccine (VarV) has a stable and favorable

BEIJING, January 20, 2026 – Co-administration of SINOVAC’s live attenuated varicella vaccine (VarV) and trivalent inactivated influenza vaccine (Anflu®) was shown to be safe and immunogenic in in heal

BEIJING, Jan. 7, 2026 – On January 6, 2026, Sinovac Life Sciences Co., Ltd., a subsidiary of Sinovac Biotech Ltd. (“SINOVAC” or the “Company”), initiated the enrollment of volunteer subjects for a Pha

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Co

BEIJING -- Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the dire

BEIJING, Jan. 4, 2026 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the